Tirofiban in Stenting for Long Coronary Lesion

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 748 participants.

Also called NCT01498003

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 748 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01498003
Other papers using this trial's data
  • Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2015-03 DOI, PubMed 25630513

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01498003. Randomized; no masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2014-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tirofiban in Stenting for Long Coronary Lesion
Acronym
PETITION
Intervention (Drug)
tirofiban
Intervention (Drug)
normal saline solution
Lead sponsor
Shanghai Jiao Tong University School of Medicine (class: other)

Record details

Record id
cardio:ct-nct01498003
Content hash
bab6a53fa0d6ca051698d8b90a077dc5083d2d07649e1c77feeed19eb161f5ce